Amplitude Surgical: Consolidated 9-Month Sales of €75.4 Million, up 15.8% at Constant Exchange Rates
20 Avril 2023 - 6:00PM
Business Wire
- Consolidated sales of €75.4m, +15.8% at constant exchange
rates, after application of IFRS 5
- Updating of the Group’s 2022-2023 guidance excluding Novastep
(foot and ankle activities): sales of approximately €100 million
and an EBITDA margin of between 26% and 27%
Regulatory News:
Amplitude Surgical (ISIN: FR0012789667, Ticker: AMPLI, eligible
for PEA-PME plans) (Paris:AMPLI), a leading French player on the
surgical technology market for lower-limb orthopedics, announces
its sales for the third quarter and first 9 months of its 2022-23
financial year.
Olivier Jallabert, Amplitude Surgical’s CEO, said: “In
the first 9 months of our 2022-23 financial year, Amplitude
Surgical posted sales growth, after application of IFRS 5 and
corresponding solely to knee and hip activity, of 15.8%. Knee and
hip activity notably grew thanks to the 19.1% increase in activity
in France, which benefited from a positive sales dynamic and
near-normal operating room availability, which wasn’t the case
during the first 9 months of the previous financial year”.
Consolidated 9-month sales
9M 2022-23
sales
31/03/2023
31/03/2022
Δ at current exchange
rates
Δ at constant exchange
rates
€ thousands - IFRS
Knee and hip activity
75,417
64,565
16.8%
15.8%
Sales post IFRS 5
75,417
64,565
16.8%
15.8%
Feet and ankles (Novastep)
18,201
12,690
43.4%
36.1%
Sales pre IFRS 5
93,618
77,255
21.2%
19.2%
Q3 2022-23
sales
31/03/2023
31/03/2022
Δ at current exchange
rates
Δ at constant exchange
rates
€ thousands - IFRS
Knee and hip activity
30,209
24,378
23.9%
24.2%
Sales post IFRS 5
30,209
24,378
23.9%
24.2%
Feet and ankles (Novastep)
6,997
4,778
46.4%
43.5%
Sales pre IFRS 5
37,206
29,156
27.6%
27.4%
For its consolidated annual accounts to June 30, 2022, the Group
applied IFRS 5 by classifying foot and ankle activities as
“Non-current assets held for sale”. The Group’s consolidated sales
for the first nine months of its 2022-23 financial year thus
correspond solely to sales generated by knee and hip activity. On
April 3, 2023, Amplitude Surgical announced the signing of a
definitive agreement for the sale of Novastep’s activities. This
operation remains subject to the approval of the competent
regulatory authorities during the second quarter of 2023.
Over the first 9 months of its 2022-23 financial year (July 2002
- March 2023), Amplitude Surgical recorded sales after application
of IFRS 5 of €75.4 million, up 16.8% in actual terms and 15.8% at
constant exchange rates. Group sales after application of IFRS 5
correspond to sales generated by knee and hip activity.
Activity in France was up by 19.1%, international distributors
generated growth of 10.3% and the Group’s international
subsidiaries saw sales increase by 11.2% in actual terms and 6.6%
at constant exchange rates.
In France, the Group benefited from a positive sales dynamic and
near-normal operating room availability, compared with the first 9
months of the previous financial year (2021-22) that saw reduced
operating room availability and the postponement of surgical
procedures.
For international subsidiaries, the global performance increased
but the level of activity varied by region: activity grew in
Brazil, Benelux and South Africa but was down in Australia and
Germany.
Group outlook
Following the press release of April 3, 2023 announcing the
signing of a definitive agreement for the divestment of Novastep’s
foot and ankle activities, the Company has updated its 2022-23
annual guidance excluding foot and ankle activities. The previous
guidance update in the press release of February 23 included
figures from Novastep’s activity. Based on the activity generated
over the first nine months of its financial year and last quarter’s
sales activity indicators, the Company is now expecting, for its
entire 2022-23 financial year to June 30, 2023:
• sales of around €100 million for knee and hip activity;
and
• an EBITDA margin of between 26% and 27% for knee and hip
activity.
Next press release:
2022-23 full-year sales, on Thursday July 21, 2023, after
market.
About Amplitude Surgical
Founded in 1997 in Valence, France, Amplitude Surgical is a
leading French player on the global surgical technology market for
lower-limb orthopedics. Amplitude Surgical develops and markets
high-end products for orthopedic surgery covering the main
disorders affecting the hip, knee and extremities, and notably foot
and ankle surgery. Amplitude Surgical develops, in close
collaboration with surgeons, numerous high value-added innovations
in order to best meet the needs of patients, surgeons and
healthcare facilities. A leading player in France, Amplitude
Surgical is developing abroad through its subsidiaries and a
network of exclusive distributors and agents distributing its
products in more than 30 countries. Amplitude Surgical operates on
the lower-limb market through the intermediary of its Novastep
subsidiaries in France and the United States. At June 30, 2022,
Amplitude Surgical had a workforce of 460 employees and recorded
sales of nearly 104.8 million euros (including foot and ankle
activity and before application of IFRS 5).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230420005596/en/
Amplitude Surgical CFO Dimitri Borchtch
finances@amplitude-surgical.com +33 (0)4 75 41 87 41
NewCap Investor Relations Thomas Grojean
amplitude@newcap.eu +33 (0)1 44 71 94 94
NewCap Media Relations Nicolas Merigeau
amplitude@newcap.eu +33 (0)1 44 71 94 98
Amplitude Surgical (EU:AMPLI)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Amplitude Surgical (EU:AMPLI)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024